Inhibice systému renin-angiotenzin-aldosteron u srdečního selhání aneb od obecného souhlasu (CONSENSUS) po vzorec myšlení (PARADIGM-HF)
[Inhibition of renin-angiotensin-aldosterone system in heart failure, or from CONSENSUS to PARADIGM-HF]
Language Czech Country Czech Republic Media print
Document type Journal Article, Review
PubMed
26075858
PII: 52343
- MeSH
- Angiotensin Receptor Antagonists therapeutic use MeSH
- Angiotensin-Converting Enzyme Inhibitors therapeutic use MeSH
- Consensus * MeSH
- Humans MeSH
- Renin-Angiotensin System drug effects MeSH
- Heart Failure drug therapy metabolism MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Review MeSH
- Names of Substances
- Angiotensin Receptor Antagonists MeSH
- Angiotensin-Converting Enzyme Inhibitors MeSH
An historical survey is presented of mortality trials on angiotensin-aldosteron system inhibition in patients with chronic heart failure. From the CONSENSUS trial up to the PARADIGM-HF trial, ACE inhibitors/angiotensin II receptor antagonists (AT1-blockers, ARBs, sartans), along with mineralocorticoid receptor blockers, have been the gold standard of treatment. Both direct renin blocker aliskiren and dual blocker enalapril + neprilysin proved ineffective; on the other hand, the new dual inhibitor valsartan + neprilysin LCZ 696 is a new and promising therapeutic agent for future treatment of chronic heart failure.
